Dernières nouvelles pour Nuvectis Pharma (NASDAQ:NVCT) Stock

Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Nuvectis Pharma Inc

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq").

News

AFMD

Affimed Receives Nasdaq Delisting Notice; Trading To Be Suspended May 20

HC Wainwright &amp; Co. analyst Sameer Joshi maintains Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) with a Buy and lowers the price target from $8 to $5.

Price Target

Analyst Ratings

BLNK

HC Wainwright & Co. Maintains Buy on Blink Charging, Lowers Price Target to $5

Integrated Platform Delivers Enhanced Visibility, Efficiency and Scalability for Forestry Operations
WESTMINSTER, Colo., May 14, 2025 /PRNewswire/ -- Trimble&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) today launched Trimble Forestry One, a comprehensive technology platform built to connect and streamline forestry operations. Unveiled at the Trimble Forestry User Conference, Forestry One enhances forest management by leveraging Trimble's common data environment for seamless integration with Trimble Connected Forest&#xAE; solutions, while also simplifying regulatory compliance and optimizing supply chain management.

TRMB

Trimble Unveils Forestry One To Connect And Streamline Forestry Operations

On Tuesday, May 13th, U.S. markets closed mixed; the S&amp;P 500 and Nasdaq closed higher for a second day as cooling April inflation and a U.S.-China trade truce boosted investor confidence. The Dow slipped, weighed down by a steep drop in UnitedHealth shares. Traders expect the Fed to hold off on rate cuts until later this year, as recession concerns eased.
According to economic data, April U.S. inflation came in slightly below expectations, with headline CPI and core CPI rising by 0.2% month-over-month. Year-over-year, CPI slowed to 2.3%, while core CPI held steady at 2.8%, matching forecasts.
Six of the S&amp;P 500&#8217;s 11 major sectors ended the day higher, with technology leading the gains. Healthcare was the weakest performer, posting the largest decline.
The Dow Jones Industrial Average declined 0.64% to 42,140.43, the S&amp;P 500 gained 0.72% to 5,886.55, and the Nasdaq surged 1.61% to 19,010.09.
Asia Markets Today
<ul class="wp-block-list">
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed 0.14% lower at 38,130.50, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.13%, ending the session at 8,279.60, led by gains in the Energy, IT, and Resources sectors.</li>
<li>India&#8217;s Nifty 50 was up 0.32% at 24,658.40, and Nifty 500 rose 0.60% to 22,483.85.</li>
<li>China&#8217;s Shanghai Composite gained 0.86% to 3,403.95, and the Shanghai Shenzhen CSI 300 was up 1.21% to 3,943.21.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session 2.30% higher at 23,640.65.</li>
</ul>
Eurozone at 05:45 AM ET
<ul class="wp-block-list">
<li>The European STOXX 50 index was down 0.55%.</li>
<li>Germany&#8217;s DAX index declined 0.41%.</li>
<li>France&#8217;s CAC 40 fell 0.64%.</li>
<li>The U.K.&#8217;s FTSE 100 index traded lower by 0.11%.</li>
</ul>
Commodities at 05:45 AM ET
<ul class="wp-block-list">
<li>Crude Oil WTI was trading lower by 1.18% at $62.91/bbl, and Brent was down 1.13% at $65.88/bbl.</li>
<li>Oil prices dipped as traders anticipated a U.S. inventory build, despite support from a U.S.-China tariff pause and easing demand concerns amid broader geopolitical and trade-related developments.</li>
<li>Natural Gas declined 1.81% to $3.581.</li>
<li>Gold was trading lower by 0.26% at $3,239.34, Silver was down 0.44% to $32.953, and Copper fell 0.49% to $4.7000.</li>
<li>Gold prices fell in Asia as easing U.S.-China trade tensions and soft U.S. inflation data reduced safe-haven demand.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.04%, S&amp;P 500 futures declined 0.05%, and Nasdaq 100 futures fell 0.03%.
Forex at 05:45 AM ET
<ul class="wp-block-list">
<li>The U.S. Dollar Index declined 0.63% to 101.35, USD/JPY was down 1.15% to 145.81, and USD/AUD fell 0.20% to 1.5421.</li>
<li>The U.S. dollar fell further on Wednesday after weaker April inflation data raised expectations for Fed rate cuts.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Gain, Europe Dips, Dollar Pressured By Soft Inflation Data - Global Markets Today While US Slept

HC Wainwright &amp; Co. analyst Andrew Fein maintains Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) with a Buy and lowers the price target from $20 to $14.

ANNX

HC Wainwright & Co. Maintains Buy on Annexon, Lowers Price Target to $14

Major brokerages have gone back on their U.S. recession forecasts after a<a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert"> 90-day tariff pause </a>between U.S. and China.
What Happened: Goldman Sachs reduced its U.S. recession odds from 45% to 35%, and Barclays ruled out a recession completely. J.P. Morgan now predicts the likelihood at less than 50%, according to Reuters.
The revised predictions come after both countries agreed to reduce tariffs: the U.S. dropped its duties on Chinese imports from 145% to 30%, and China lowered its rates on U.S. goods from 125% to 10%.
Goldman also raised its 2025 GDP forecast by 0.5 points to 1%. It now projects three Fed rate cuts: one in December 2025, and two more in March and June 2026. Goldman had earlier predicted all three cuts in 2025 beginning from July.
Barclays and J.P. Morgan also now expect a single rate cut, both in December.
Citigroup changed its expected cut from June to July.
In addition, Goldman lifted its S&amp;P 500 year-end target from 5,900 to 6,100, referring to lower tariff risks.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45397930/trump-memecoin-adopted-by-china-linked-nasdaq-company-as-treasury-reserve-asset">Trump Memecoin Adopted By China-Linked Nasdaq Company As Treasury Reserve Asset</a>
Why It Matters: While these major brokerage firms have walked back on their recession predictions after the 90-day pause announcement, analysts like Jim Cramer believe that <a href="https://www.benzinga.com/25/05/45373515/jim-cramer-says-bulls-need-steady-drip-of-trade-deals-to-assure-market-about-recession-and-inflation">"steady drip of trade deals"</a> are crucial to boost the market and allay fears of a recession. 
Google searches for &#8220;Are we in a recession&#8221; have increased to their <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45337839/if-you-have-to-google-are-we-in-a-recession-you-probably-feel-like-it">second-highest level ever</a>, indicating growing public anxiety over the state of the U.S. economy.
Meanwhile, despite coming to a <a href="https://www.benzinga.com/markets/25/05/45374966/xi-jinping-warns-bullying-and-hegemony-will-only-result-in-self-isolation-in-first-remarks-since-us-china-tariff-suspension">tariff pause agreement</a> with the U.S., China is holding firm in its stance against coercion, with President Xi Jinping saying, "There are no winners in tariff wars and trade wars," and that, "bullying and hegemony will only result in self-isolation," obtusely referring to the U.S.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45396754/bill-gates-slams-trumps-tariffs-we-told-china-to-make-their-own-chips-and-theyre-making-great-progre">Bill Gates Slams Trump&#8217;s Tariffs: We Told China To &#8216;Make Their Own Chips&#8217; —And &#8216;They&#8217;re Making Great Progress,&#8217; Warns It&#8217;s A &#8216;Bad Time To Interject So Much Uncertainty&#8217;</a></li>
</ul>
Image Via Shutterstock

Economics

General

Goldman Sachs, Barclays, JPM Walk Back US Recession Forecasts After 90-Day US-China Tariff Truce — Fewer Fed Cuts Expected In 2025

Xenia Hotels &amp; Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) ("Xenia" or the "Company") today announced that its Board of Directors authorized a cash dividend of $0.14 per share of the Company's common stock for the second quarter 2025. The dividend will be paid on July 15, 2025, to all holders of record of the Company's common stock as of the close of business on June 30, 2025.
In addition, the Company's Board of Directors authorized the repurchase of up to an additional $100 million of the Company's outstanding common shares. Repurchases may be made in the open market and privately negotiated transactions, or by other means, including Rule 10b5-1 trading plans. The repurchase program may be suspended or discontinued at any time and does not obligate the Company to acquire any particular amount of shares. Inclusive of this additional authorization, the Company had approximately $180 million remaining under its total repurchase authorization as of May 13, 2025.

Buybacks

Xenia Hotels Declares $0.14 Dividend, Adds $100M to Share Buyback Program

Orezone Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ORE#TSX">ORE</a>) reported quarterly earnings of $0.04 per share. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported $82.72 million in sales this quarter. This is a 27.87 percent increase over sales of $64.69 million the same period last year.

Earnings

TSX:ORE

Orezone Gold Q1 Adj. EPS $0.04 Up From $0.02 YoY, Sales $82.72M Up From $64.69M YoY

Franklin Street Properties Announced That Its Board Of Directors Has Initiated A Review Of Strategic Alternatives In Order To Explore Ways To Maximize Shareholder Value

Management

TXNM

The Board Of Directors Of Txnm Energy Announced The Transition Of Current Chief Executive Officer Pat Collawn To Executive Chair, Effective July 1, 2025

DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 40 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $6.75 million which missed the analyst consensus estimate of $7.48 million by 9.68 percent. This is a 17.26 percent increase over sales of $5.76 million the same period last year.

Earnings Misses

DRIO

DarioHealth Q1 Adj. EPS $(0.12), Inline, Sales $6.75M Miss $7.48M Estimate

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) is looking for FY2026 Adj EPS of $1.56-$1.59 vs $1.54 analyst estimate. sees sales of $1.950 billion-$1.965 billion vs $1.94 billion analyst estimate.

Guidance

Dynatrace Sees FY2026 Adj EPS $1.56-$1.59 vs $1.54 Est; Sees Sales $1.950B-$1.965B vs $1.94B Est

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) is looking for Q1 Adj EPS of $0.37-$0.38 vs $0.35 analyst estimate. sees sales of $465.000 million-$470.000 million vs $454.51 million analyst estimate.

Dynatrace Sees Q1 Adj EPS $0.37-$0.38 vs $0.35 Est; Sees Sales $465.000M-$470.000M vs $454.51M Est

Trimble Launched Trimble Forestry One, A Comprehensive Technology Platform Built To Connect And Streamline Forestry Operations

RCAT

Red Cat Announced The Expansion Of Its Multi-domain Family Of Systems With A New Line Of Unmanned Surface Vessels

Howard Hughes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) surged 2.78% during Wednesday pre-market, after non-Executive Director, Bill Ackman, stepped down from the Board of Directors of Universal Music Group N.V. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UMGNF#OTC">UMGNF</a>). The decision comes in light of new obligations towards Howard Hughes that Ackman has undertaken.
What Happened: As per a press release from Universal Music Group, the music label representing Taylor Swift, Ackman has chosen to resign from his role as a non-executive director with immediate effect. This decision is linked to new executive and board duties resulting from Ackman&#8217;s commitments in Pershing Square Capital Management as well as his recent investments, such as Howard Hughes Holding.
During his tenure at UMG, Ackman witnessed the company&#8217;s transformation from a private entity to a successful public enterprise. He commended the&nbsp;leadership of Sir Lucian Grainge&nbsp;and the UMG team, asserting that the company is &#8220;extremely well positioned for future&nbsp;growth and profitability,&#8221; as per a press release from Pershing Square.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/05/45394734/bernie-sanders-says-american-workers-are-angry-because-wages-havent-kept-up-they-are-lower-today-than-they-w" target="_blank" rel="noreferrer noopener">Bernie Sanders Says &#8216;American Workers Are Angry&#8217; Because Wages Haven&#8217;t Kept Up—&#8217;They Are Lower Today Than They Were 52 Years Ago&#8217;</a>
Why It Matters:&nbsp;Ackman, founder and CEO of Pershing Square, has been a major investor in UMG since 2021. In March this year, his firm <a href="https://www.benzinga.com/25/03/44330386/bill-ackman-sells-portion-of-universal-music-stake-one-of-the-best-businesses-we-have-ever-owned">sold </a>a 2.7% stake in the music company, raising $1.4 billion, after initially acquiring around 10% of UMG.
Ackman&#8217;s belief in UMG&#8217;s long-term growth trajectory has been evident throughout his tenure on the board. In a letter to investors in March, he expressed his confidence in UMG&#8217;s future prospects, citing continued penetration of streaming, recurring price increases, and new product tiers for superfans as the driving factors for the company&#8217;s next era of growth.
Ackman's departure from Universal's board comes on the heels of UMG's Q1 2025 financial results, which reported a 9.5% year-over-year increase in revenue and a 10% rise in adjusted EBITDA at constant currency.
Earlier this month, Ackman <a href="https://www.benzinga.com/news/asset-sales/25/05/45193332/ackmans-900-million-power-play-pershing-square-takes-massive-stake-in-howard-hughes-with-48-premium">increased his stake</a> in real estate firm Howard Hughes Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) to 46.9%, investing an additional $900 million, as part of his goal to build a diversified holding company inspired by Warren Buffett's Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>).
On Tuesday, the OTC shares of Universal Music Group rose 3.24% to close at $30.94. On a year-to-date basis, it gained 23.91%. 
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45379271/fartcoin-nets-trader-7-million-in-unrealized-gains-but-he-refuses-to-cash-out-it-is-priming-for-the-move" target="_blank" rel="noreferrer noopener">Fartcoin Nets Trader $7 Million In Unrealized Gains, But He Refuses To Cash Out: &#8216;It Is Priming For THE Move&#8217; &#8211; Benzinga</a></li>
</ul>
Image created using artificial intelligence via Midjourney.
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

UMGNF

Howard Hughes Rises Nearly 3% In Pre-Market As Bill Ackman Exits From Universal Music Group's Board To Prioritize New Investments

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.30 by 10 percent. This is a 10 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $445.17 million which beat the analyst consensus estimate of $434.78 million by 2.39 percent. This is a 16.89 percent increase over sales of $380.85 million the same period last year.

Earnings Beats

Dynatrace Q4 Adj. EPS $0.33 Beats $0.30 Estimate, Sales $445.17M Beat $434.78M Estimate

MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.30 by 40 percent. This is a 10.53 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $261.19 million which beat the analyst consensus estimate of $255.93 million by 2.06 percent. This is a 22.90 percent increase over sales of $212.53 million the same period last year.

MMYT

MakeMyTrip Q4 Adj. EPS $0.42 Beats $0.30 Estimate, Sales $261.19M Beat $255.93M Estimate

<ul>
<li>Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders.</li>
<li>Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation.</li>
</ul>
Key highlights from the company's three poster presentations at ASGCT are below.
<a href="https://www.globenewswire.com/Tracker?data=9yX8a0siWUu86CPPpMs78hcSclIKkQlHcOyOy7e9xdpb2h3iGyDxA83ihILdBnjw1HQHaS2CbxHVuCWMTH0w57JoTAv2b3WeMSuzDqdT4CcFlapWqyMBF4OtT6sLv43f8ShQBhSCiwrTDSwnTmHHUtBm5GdndrKZibF8MLDKDxgXe-5xf4aJnbibP3g4e81XaOMuDKRa2TxPfEm_NspaTMnRTVglZpXZIVLUMECAJfmavFXTHugoE-4vOk0sHhZn">A Compact and Potent Type II CRISPR System for CNS Gene Knockdown via AAV Delivery</a>
<ul>
<li>MG21-1 is a novel, compact type II nuclease comprising 1,098 amino acids that, when delivered with its guide RNA in a single adeno-associated virus (AAV), achieved strong protein knockdown in the CNS.</li>
<li>In vivo, localized injection of AAV9 packaged with MG21-1 in the mouse motor cortex produced up to 69% target protein reduction.</li>
<li>Systemic delivery with a blood-brain barrier-crossing capsid resulted in 82% protein knockdown in the brain and 71% in the brainstem.</li>
<li>These results demonstrate the potential of a small CRISPR nuclease to efficiently knock-down targets in the CNS using a single AAV injected locally or systemically.</li>
</ul>
<a href="https://www.globenewswire.com/Tracker?data=z7WKpuXB4eDrDGOE23u9TFcEu0CtaS12WlveJxpCODdSfO_DwJU_kZyca3RZr6BtxcLv77FA7mqyYZIkfXYFn9WDK3ry-6OthXJ5TEccYich9Lr3Fay3ff-ksWEuaMaRj2k7OCHjEN_WVUht2DXoU0Sd2iAOaDWX-0YXvNCqWe1e-yRRbM52WGTYVEVDAiZ9HL4fTj4Hq8ii5qwuEM3W7Nv383eU3ORRwvJgcICl-CGZvmdc2K2t1vpd-VIe9HW6">In Vivo Genome Editing with an Ultra-Compact Type V Nuclease for All-In-One AAV Delivery&nbsp;</a>
<ul>
<li>MG119-28 is an ultra-compact engineered type V nuclease consisting of 488 amino acids and capable of efficient genome editing across multiple cultured cell tissues when delivered using a single AAV vector.</li>
<li>In vitro, this nuclease restored dystrophin protein levels by over 50% in Duchenne muscular dystrophy (DMD) model myocytes and achieved complete gene disruption at a therapeutically relevant target locus in K562 human cells.</li>
<li>In vivo, AAV9-mediated delivery to the mouse CNS via stereotactic injection resulted in up to 52% editing efficiency in olfactory bulb nuclei and produced 64% knockdown of the target protein in the motor cortex.</li>
<li>These results highlight the potential of this ultra-compact nuclease to deliver AAV-based therapeutic genome editing beyond the liver, with implications for treating neuromuscular and neurodegenerative disorders.</li>
</ul>
<a href="https://www.globenewswire.com/Tracker?data=p5HPOOwWH3cfhRJHO9Y-K3uk7xtoptN2P-I-Www9_TzyMETbO5ScRth_f3PwunltWyzUlub2CaTfszNfEAzlxwoKSwuIsbEhcgIYC3mltru5_nfj2L57QG3kXcrLSOr89Y6hBGwvvM-61OJ-F4MumqlCiRGrmlgknmdNbOlIBvFIA0jfyVANKVxcCRdzVyeL2kl2WJksw2bzP4GxvRxdRsR2oZ_HoPbbdLAesokYtn2sxntNmtcT2DHV2lEbfuxe9l_O_4uyxtR88N8PZWi-IRg_TeGk7riV6SS_fMCaKRrZLxYhSHxG73y8dVqs1mWGWboeMbl2n3WyFksBewIGcQ==">Site-Specific Integration of Therapeutic Transgenes with a Type V-K CAST System Engineered for Efficient and Targeted Human Genome Editing&nbsp;</a>
<ul>
<li>The data demonstrate that CRISPR-associated transposases (CAST) protein engineering and delivery optimization enables efficient integration of diverse cargo designs across different cell types and target loci, including with therapeutically relevant delivery approaches that are required for in vivo editing.</li>
<li>Through structure and AI-guided protein design, integration efficiency of a compact type V-K CAST system derived from uncultivated microbes was improved by &gt;50x compared with the natural system.</li>
<li>Functional activity translated to primary mammalian cells, a key step in development for human therapeutic applications.</li>
<li>These results suggest that type V-K CAST are promising systems for site-specific programmable integration of gene-sized donors for therapeutic and biotechnological development.</li>
</ul>

Biotech

Health Care

Metagenomi Announced The Presentation Of Three Abstracts At The American Society Of Gene & Cell Therapy Annual Meeting

LuxExperience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUXE#NYSE">LUXE</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.01) by 700 percent. This is a 20 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $255.01 million which beat the analyst consensus estimate of $246.70 million by 3.37 percent. This is a 0.39 percent increase over sales of $254.02 million the same period last year.

LUXE

LuxExperience Q3 Adj. EPS $0.06 Beats $(0.01) Estimate, Sales $255.01M Beat $246.70M Estimate

Press Releases

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

Comments

Nuvectis Pharma

Actualités

Dernières nouvelles pour Nuvectis Pharma (NASDAQ:NVCT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL